Enteric fever, predominantly caused by Salmonella Typhi and Paratyphi, poses a significant global health burden. Despite advancements in healthcare, managing this illness remains a challenge due to the increasing resistance to antibiotics. This article aims to provide a comprehensive guide to healthcare professionals for the effective management of enteric fever.
Early diagnosis is crucial for effective management. Blood culture remains the gold standard for diagnosis, although molecular methods like PCR are increasingly being used for their higher sensitivity and specificity. Rapid diagnostic tests, while less specific, can provide early presumptive diagnosis.
Antibiotic therapy forms the cornerstone of treatment. The choice of antibiotic should be guided by local susceptibility patterns. Fluoroquinolones, ceftriaxone, and azithromycin are commonly used. However, the emergence of extensively drug-resistant strains necessitates regular surveillance and judicious use of antibiotics.
Supportive care is integral to management. Adequate hydration, correction of electrolyte imbalances, and management of complications such as intestinal perforation or haemorrhage are vital. Nutritional support plays a key role in enhancing the patient's immune response and promoting recovery.
Vaccination is an effective preventive measure against enteric fever. Two vaccines, Vi polysaccharide and Ty21a, are currently available and recommended for high-risk groups and travellers to endemic areas. Efforts are ongoing to develop more effective vaccines.
Effective management of enteric fever requires a multi-pronged approach, including early diagnosis, appropriate antibiotic therapy, supportive care, and vaccination. Continuous surveillance and research are needed to address the challenges posed by antibiotic resistance and to develop more effective vaccines. Healthcare professionals play a pivotal role in implementing these strategies and mitigating the global burden of enteric fever.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation